HK1048955A1 - 朊病毒蛋白肽及其應用 - Google Patents

朊病毒蛋白肽及其應用

Info

Publication number
HK1048955A1
HK1048955A1 HK03101306.4A HK03101306A HK1048955A1 HK 1048955 A1 HK1048955 A1 HK 1048955A1 HK 03101306 A HK03101306 A HK 03101306A HK 1048955 A1 HK1048955 A1 HK 1048955A1
Authority
HK
Hong Kong
Prior art keywords
prion protein
protein peptides
prp
therapeutic
antibodies specific
Prior art date
Application number
HK03101306.4A
Other languages
English (en)
Inventor
R Cashman Neil
Paramithiotis Eustache
Slon-Usakiewicz Jacek
Haghighat Ashkan
Pinard Mare
Lawton Trebor
Original Assignee
Idexx Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22492135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1048955(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idexx Lab Inc filed Critical Idexx Lab Inc
Publication of HK1048955A1 publication Critical patent/HK1048955A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK03101306.4A 1999-06-23 2003-02-20 朊病毒蛋白肽及其應用 HK1048955A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14063499P 1999-06-23 1999-06-23
PCT/US2000/017455 WO2000078344A1 (en) 1999-06-23 2000-06-23 Prion protein peptides and uses thereof

Publications (1)

Publication Number Publication Date
HK1048955A1 true HK1048955A1 (zh) 2003-04-25

Family

ID=22492135

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101306.4A HK1048955A1 (zh) 1999-06-23 2003-02-20 朊病毒蛋白肽及其應用

Country Status (12)

Country Link
EP (1) EP1194164B8 (zh)
JP (1) JP2003521477A (zh)
CN (1) CN1370078A (zh)
AT (1) ATE348632T1 (zh)
AU (1) AU783484B2 (zh)
CA (1) CA2377648A1 (zh)
DE (1) DE60032486T2 (zh)
ES (1) ES2278617T3 (zh)
HK (1) HK1048955A1 (zh)
MX (1) MXPA01013186A (zh)
NZ (1) NZ516240A (zh)
WO (1) WO2000078344A1 (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
WO2002000713A1 (en) * 2000-06-26 2002-01-03 Universität Zürich Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen
US7303907B2 (en) 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
GB2376071A (en) * 2001-05-31 2002-12-04 Mini Agriculture & Fisheries Method for typing a TSE strain
GB2379737A (en) * 2001-09-05 2003-03-19 Univ Geneve Diagnostic method for spongiform encephalopathy disease
WO2003040685A2 (en) * 2001-11-09 2003-05-15 King's College London Diagnosis demyelinating or spongiform disease
AU2003205623A1 (en) * 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates
EP1572937B1 (en) 2002-04-09 2012-02-08 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
EP1382971A1 (en) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection of prion disease
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
JP4279836B2 (ja) * 2002-10-30 2009-06-17 プロテオメ サイエンシス ピーエルシー 牛海綿状脳症（ｂｓｅ）の判定方法
GB0227886D0 (en) 2002-11-29 2003-01-08 Medical Res Council Prion inhibition
EP2312318B1 (en) * 2002-12-03 2014-10-08 North Carolina State University Prion protein ligands and methods of use
CN1297663C (zh) * 2003-05-07 2007-01-31 中国科学院微生物研究所 一类重组基因产生的朊蛋白（PrPC）融合变构体及其用途
KR101166012B1 (ko) 2003-08-13 2012-07-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 프리온-특이적 펩티드 시약
US20070003977A1 (en) * 2003-08-20 2007-01-04 Amorfix Life Sciences Ltd Epitope protection assay and method for detecting protein conformations
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
AU2005209592B2 (en) 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
US7482172B2 (en) 2005-09-19 2009-01-27 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
NZ594844A (en) 2005-09-09 2013-04-26 Novartis Ag Prion-specific peptoid reagents
US7794692B2 (en) 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
JP5823663B2 (ja) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物
US7601506B2 (en) 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
US9056918B2 (en) 2008-04-25 2015-06-16 University Of Saskatchewan Prion epitopes and methods of use thereof
EP2128618A1 (en) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. A process for monitoring the presence of pathogenic agents in biological fluids by nanostructured materials
DK2342220T3 (da) * 2008-10-06 2021-08-09 Univ British Columbia Metoder og systemer til forudsigelse af misfoldede proteinepitoper
AU2010229858A1 (en) 2009-03-25 2011-09-22 Los Alamos National Security, Llc Fiber optical assembly for fluorescence spectrometry
CN102365096A (zh) * 2009-03-25 2012-02-29 洛斯阿拉莫斯国家安全有限责任公司 传染剂的快速死前检测
TWI419711B (zh) * 2010-07-27 2013-12-21 Univ Nat Changhua Education Tyrosinase polypeptide inhibitor
CN102492018A (zh) * 2010-07-27 2012-06-13 萧乃文 酪氨酸酶多肽抑制剂
AU2012207454B2 (en) * 2011-01-18 2016-11-17 Prionics Ag Methods for amplification and detection of prions
US9296819B2 (en) * 2012-06-12 2016-03-29 Promis Neurosciences Inc. Antibodies and conjugates that target misfolded prion protein
US9809620B2 (en) 2013-04-30 2017-11-07 University Of Saskatchewan Prion disease-specific epitopes and methods of use thereof
CN108409865A (zh) * 2018-01-19 2018-08-17 鄞州出入境检验检疫局综合技术服务中心 特异性双酚a羊多克隆抗体及其应用
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177754T1 (de) * 1991-12-03 1999-04-15 Proteus Molecular Design Fragmente von prion proteinen.
WO1993023432A1 (en) * 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
AU707484B2 (en) * 1995-09-14 1999-07-08 Regents Of The University Of California, The Antibodies specific for native PrPsc
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
EP0861900A1 (en) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
EP1194164A1 (en) 2002-04-10
ES2278617T3 (es) 2007-08-16
EP1194164B1 (en) 2006-12-20
AU783484B2 (en) 2005-11-03
AU5637500A (en) 2001-01-09
DE60032486D1 (de) 2007-02-01
MXPA01013186A (es) 2002-08-12
ATE348632T1 (de) 2007-01-15
EP1194164A4 (en) 2004-09-08
JP2003521477A (ja) 2003-07-15
WO2000078344A8 (en) 2001-11-15
EP1194164B8 (en) 2007-03-21
WO2000078344A1 (en) 2000-12-28
DE60032486T2 (de) 2007-08-16
CA2377648A1 (en) 2000-12-28
NZ516240A (en) 2005-11-25
CN1370078A (zh) 2002-09-18

Similar Documents

Publication Publication Date Title
HK1048955A1 (zh) 朊病毒蛋白肽及其應用
IL157946A0 (en) Combination therapy
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
HK1048831A1 (en) Human ctla-4 antibodies and their uses
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
SG157951A1 (en) Cripto blocking antibodies and uses thereof
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
IL125590A0 (en) Peptide immunogens
AU3841601A (en) Modified factor viii
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
AU7216498A (en) Inhibitors of the urokinase receptor
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
NZ514691A (en) Method to type prion proteins
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof